Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, today announced that they are scheduled to present at the 3rd Annual Rational Combinations 360o event in Philadelphia, PA on September 13, 2018 at 1:50 PM ET.
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, today announced that they are scheduled to present at the 3rd Annual Rational Combinations 360o event in Philadelphia, PA on September 13, 2018 at 1:50 PM ET.
The presentation, entitled “Demystifying Tumor Immunogenomics: Key Challenges and Solutions,” will discuss how the Personalis ACE ImmunoID Platform overcomes the limitations associated with conventional NGS approaches that are used in the preclinical and clinical development of new oncology therapeutics.
ACE ImmunoID is a universal immunogenomics platform, purpose-built for modern precision oncology applications, combining highly-sensitive exome and transcriptome sequencing with advanced analytics. The platform provides a multidimensional view of the tumor, its microenvironment, as well as its repertoire of tumor-specific neoantigens.
The Personalis presentation will be delivered by Erin N. Newburn, PhD, Associate Director, Field Applications Scientist.
About Personalis, Inc.
Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005430/en/
Source: Personalis, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180912005430/en
